NewLink Genetics Finds Collaborator in Genentech for IDO Pathway Inhibitors
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 11 (Table of Contents)
Published: 7 Nov-2014
DOI: 10.3833/pdr.v2014.i11.2073 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a deal that signals an important role for IDO (indoleamine 2, 3-dioxygenase) inhibitors in the rapidly evolving immuno-oncology field, Ebola vaccine developer NewLink Genetics has licensed its Phase I IDO pathway inhibitor NLG919 to Roche’s Genentech for US$150 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS